FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status - a Phase II Study by the GONO Group

被引：1
|
作者：
Fornaro, L. [1 ]
Loupakis, F. [1 ]
Lonardi, S. [2 ]
Masi, G. [1 ]
Salvatore, L. [1 ]
Cremolini, C. [1 ]
Bergamo, F. [2 ]
Cappetta, A. [2 ]
Zagonel, V. [2 ]
Falcone, A. [1 ]
机构：
[1] Univ Pisana, Azienda Osped, UO Oncol Med Univ 2, Pisa, Italy
[2] UOC Oncol Med 1, Ist Oncol Veneto IRCCS, Padua, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71741-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S420 / S420
页数：1
相关论文
共 50 条
  • [1] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
    Falcone, A.
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Amoroso, D.
    Puglisi, M.
    Fea, E.
    Brunetti, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
    Masi, G.
    Loupakis, F.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Vasile, E.
    Cialo, A.
    Cavaciocchi, D.
    Di Leo, A.
    Puglisi, M.
    Ciprotti, M.
    Amoroso, D.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [3] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Salvatore, L.
    Fornaro, L.
    Baldi, G.
    Stasi, I
    Cupini, S.
    Ciarlo, A.
    Del Monte, F.
    Trenta, P.
    Mezi, S.
    Rondini, M.
    Andreuccetti, M.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [4] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Ciprotti, M.
    Donati, S.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
  • [5] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) IN METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS OF A PHASE II GONO TRIAL
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Di Marsico, Roberta
    Antonuzzo, Andrea
    Baldi, Giacomo Giulio
    Stasi, Irene
    Pfanner, Elisabetta
    Ciarlo, Andrea
    Del Monte, Francesca
    Conte, Davide
    Iacovelli, Roberto
    Sonaglio, Claudia
    Granetto, Cristina
    Donati, Sara
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [6] Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II GONO trial
    Masi, G.
    Salvatore, L.
    Fornaro, L.
    Vasile, E.
    Baldi, G. G.
    Stasi, I.
    Ciarlo, A.
    Tuzi, A.
    Andreuccetti, M.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
  • [7] The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (GONO).
    Falcone, A.
    Masi, G.
    Brunetti, I.
    Benedetti, G.
    Bertetto, O.
    Picone, V.
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Ricci, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 149S - 149S
  • [8] Biweekly irinotecan, oxaliplatin and infusional 5FU/LV (FOLFOXIRI) versus folfiri as first-line treatment of metastatic colorectal cancer (MCRC):: Results of a randomized phase III trial by the gruppo oncologico nord ovest (GONO)
    Masi, G.
    Allegrini, G.
    Brunetti, I.
    Murr, R.
    Ricci, S.
    Benedetti, G.
    Crino, L.
    Fanchini, L.
    Bertetto, O.
    Picone, V.
    Cortesi, E.
    Vitello, S.
    Chiara, S.
    Rosso, R.
    Granetto, C.
    Merlano, M.
    Porcile, G.
    Alabisio, O.
    Fioretto, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 7 - 7
  • [9] FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
    Fornaro, L.
    Lonardi, S.
    Masi, G.
    Loupakis, F.
    Bergamo, F.
    Salvatore, L.
    Cremolini, C.
    Schirripa, M.
    Vivaldi, C.
    Aprile, G.
    Zaniboni, A.
    Bracarda, S.
    Fontanini, G.
    Sensi, E.
    Lupi, C.
    Morvillo, M.
    Zagonel, V.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (08) : 2062 - 2067
  • [10] SECOND-LINE CHEMOTHERAPY AFTER FIRST-LINE IRINOTECAN, OXALIPLATIN AND 5-FU/LV (FOLFOXIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Marcucci, L.
    Cupini, S.
    Masi, G.
    Allegrini, G.
    Cerri, E.
    Loupakis, F.
    Ricci, S.
    Brunetti, I.
    Fontana, E.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 60 - 60
12345